Navigation Links
Edison Issues Outlook on ReNeuron Group (RENE)
Date:3/23/2017

LONDON, March 23, 2017 /PRNewswire/ --

ReNeuron reported in December 2016 positive Phase II trial data for its CTX cells in chronic stroke patients, despite not meeting the three-month time frame of a two-point improvement in its primary outcome measure, the Action Research Arm Test (ARAT). As a result, the company has confirmed that it will progress to a pivotal controlled clinical study in 2017. Beyond CTX, we expect safety and efficacy data from its retinitis pigmentosa (RP) trial in 2017 and Phase I data from its critical limb ischaemia (CLI) trial. Our rNPV has increased to £291m.

Continue Reading
Edison Logo
Edison Logo

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168)

Our rNPV-based valuation has increased to £291m (vs £278m), as we have rolled the model forward to 2017. ReNeuron is well-funded (£60m cash at end September 2016), which should enable it to execute on an expanding clinical trial programme. This could result in a number of key inflection points, including initiation of a pivotal Phase III study for CTX in stroke (H117), initiation of a Phase II clinical trial for CTX in CLI in 2017, Phase I/II human retinal progenitor cells (hRPC) data in 2017 and further preclinical data from the exosome nanomedicine platform (efficacy and toxicity).

Click here to view the full report.

All reports published by Edison are available to download free of charge from its websitehttp://www.edisoninvestmentresearch.com .

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn
http://www.linkedin.com/company/edison-investment-research

Twitter
http://www.twitter.com/Edison_Inv_Res

YouTube
http://www.youtube.com/edisonitv

Google+
https://plus.google.com/105425025202328783163/posts

For more information please contact: Dr Linda Pomeroy, Edison Investment Research, +44(0)20-3077-5738, healthcare@edisongroup.com


'/>"/>
SOURCE Edison Investment Research
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Edison Issues Initiation on Immunovia (IMMUNOV)
2. Edison Issues Initiation on Crossject
3. Edison Issues ADR Update on GW Pharmaceuticals
4. Edison Issues ADR Outlook on Bavarian Nordic
5. Edison Issues Outlook on Bavarian Nordic
6. Edison Issues Re-initiation on Hutchison China MediTech
7. Edison Issues Initiation on International Stem Cell
8. Edison Issues ADR Update on Novogen
9. Edison Issues ADR Update on BTG
10. Edison Issues ADR Update on SymBio Pharmaceuticals
11. Edison Issues ADR Update on Angle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it is ... and STI Technologies Limited to lower diabetes healthcare costs ... STI,s innoviCares card, which is available throughout all provinces ... customers will be eligible for additional savings when shopping ...
(Date:5/3/2017)... N.J. , May 3, 2017  Getinge, ... that contribute to quality enhancement and cost efficiency ... from a study of contemporary practice demonstrating that ... first-line therapy for critically ill patients. The single-center, ... Company,s newer large volume MEGA ® 50cc ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... ... , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming ... referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on ... no longer need to feel the esthetic effects of wires and brackets when they ...
(Date:5/24/2017)... Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which the ... on the pelvic structures causing inflammation and pain. Patients experiencing painful intercourse, ...
(Date:5/24/2017)... ... , ... Rob Lowe is a sought after actor, and also serves as ... public important topics from all aspects of life, and a new segment is being ... and ankles. , Podiatry is essential to people’s overall well-being, and if viewers have ...
(Date:5/23/2017)... New York City (PRWEB) , ... May 23, ... ... Record (EHR), Population Health and Clinical Integration company, announced today that its ... Patient-Centered Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards ...
Breaking Medicine News(10 mins):